Table 3 Comparisons of AD-related molecules between APOE genotype groups
From: Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer’s disease
N | β (95% CI) | P-value | |
|---|---|---|---|
APOE2 vs. APOE3 (reference) | APOE2 (N = 45) vs. APOE3 (N = 156) | ||
Aβ40-TBS | 174 | 0.36 (− 0.36, 1.08) | 0.32 |
Aβ40-TBSX | 188 | − 0.26 (− 0.78, 0.26) | 0.33 |
Aβ40-FA | 188 | 1.12 (− 2.61, 4.86) | 0.55 |
Aβ42-TBS | 186 | 0.31 (− 0.84, 1.46) | 0.59 |
Aβ42-TBSX | 192 | − 0.98 (− 2.02, 0.06) | 0.064 |
Aβ42-FA | 197 | − 1.07 (− 12.12, 9.99) | 0.85 |
apoE-TBS | 196 | 0.61 (0.29, 0.93) | < 0.001 |
apoE-TBSX | 194 | − 0.11 (− 0.26, 0.04) | 0.14 |
apoE-FA | 197 | 0.03 (− 0.46, 0.52) | 0.91 |
tTau-TBS | 176 | − 2.44 (− 7.41, 2.53) | 0.33 |
tTau-TBSX | 194 | − 0.03 (− 0.19, 0.12) | 0.66 |
tTau-FA | 201 | 0.14 (− 0.02, 0.29) | 0.079 |
pTau181-TBS | 194 | − 0.05 (− 0.23, 0.13) | 0.56 |
pTau181-TBSX | 194 | − 0.08 (− 0.21, 0.04) | 0.18 |
pTau181-FA | 192 | − 0.01 (− 0.27, 0.25) | 0.94 |
APOE4 vs. APOE3 (reference) | APOE4 (N = 152) vs. APOE3 (N = 156) | ||
Aβ40-TBS | 267 | 0.82 (0.25, 1.39) | 0.005 |
Aβ40-TBSX | 292 | 0.99 (0.51, 1.48) | < 0.001 |
Aβ40-FA | 290 | 14.04 (9.94, 18.15) | < 0.001 |
Aβ42-TBS | 289 | 2.29 (1.63, 2.96) | < 0.001 |
Aβ42-TBSX | 293 | 2.51 (1.88, 3.14) | < 0.001 |
Aβ42-FA | 303 | 24.96 (18.17, 31.75) | < 0.001 |
apoE-TBS | 303 | − 0.29 (− 0.51, − 0.06) | 0.012 |
apoE-TBSX | 296 | 0.13 (0.02, 0.23) | 0.016 |
apoE-FA | 302 | 1.24 (0.85, 1.64) | < 0.001 |
tTau-TBS | 278 | − 1.62 (− 5.16, 1.91) | 0.37 |
tTau-TBSX | 296 | − 0.18 (− 0.30, − 0.07) | 0.002 |
tTau-FA | 308 | − 0.13 (− 0.24, − 0.03) | 0.013 |
pTau181-TBS | 297 | − 0.14 (− 0.26, − 0.03) | 0.017 |
pTau181-TBSX | 295 | − 0.06 (− 0.15, 0.02) | 0.14 |
pTau181-FA | 296 | 0.72 (0.49, 0.95) | < 0.001 |